Syed Anwer, MD
Critical Care Medicine · Oklahoma City, OKNPI 1689720443
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.7% of the total across 230 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 33 manufacturers, the largest accounting for just 20.4% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $1,193, 6.8 times the $176 reported in 2019. Among critical care medicine clinicians in OK with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 230 payments — averaging $19.12 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Insmed, Inc.$897
- GSK$796
- Boehringer Ingelheim$502
- AstraZeneca$229
- Regeneron Healthcare Solutions, Inc.$219
- Sanofi$200
- plus $2K from 27 others
What the payments were for
- Food & beverage$4,387100%
- Education$120%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Insmed, Inc. | 43 | $897 |
| GSK | 57 | $796 |
| Boehringer Ingelheim | 21 | $502 |
| AstraZeneca | 13 | $229 |
| Regeneron Healthcare Solutions, Inc. | 11 | $219 |
| Sanofi | 10 | $200 |
| Mallinckrodt Hospital Products Inc. | 6 | $169 |
| Gilead | 9 | $163 |
| Novartis | 8 | $148 |
| Amgen | 8 | $141 |
| Pulmonx Corporation | 1 | $99 |
| Inogen, Inc. | 7 | $97 |
| Actelion Pharmaceuticals US, Inc. | 4 | $91 |
| Genentech USA, Inc. | 4 | $81 |
| Harmony Biosciences LLC | 4 | $70 |
| AbbVie | 2 | $61 |
| Merck | 3 | $42 |
| ANI Pharmaceuticals, Inc. | 2 | $36 |
| Fisher & Paykel Healthcare Inc | 2 | $36 |
| Baxter Healthcare | 1 | $33 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $33 |
| Advanced Respiratory, Inc | 1 | $31 |
| Masimo Corporation | 1 | $29 |
| Johnson & Johnson | 2 | $29 |
| Avadel CNS Pharmaceuticals, LLC | 1 | $23 |
| Jazz Pharmaceuticals Inc. | 1 | $23 |
| Boston Scientific | 1 | $21 |
| Shionogi Inc | 1 | $19 |
| Axsome Therapeutics, Inc. | 1 | $18 |
| Viatris Specialty LLC | 1 | $16 |
| Shire North American Group Inc | 1 | $16 |
| Pfizer | 1 | $15 |
| Phadia US Inc. | 1 | $14 |
How this compares
$4,399 in reported general payments places this provider in the 90th percentile of 57 critical care medicine providers in Oklahoma.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OfevNintedanib Esylate | 20 | $256,003 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 284 | $211,893 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 205 | $156,696 |
| Spiriva RespimatTiotropium Bromide | 78 | $48,155 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 68 | $41,497 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 60 | $29,597 |
| Breo ElliptaFluticasone/Vilanterol | 40 | $24,985 |
| Advair HfaFluticasone Propion/Salmeterol | 43 | $18,931 |
| SymbicortBudesonide/Formoterol Fumarate | 55 | $16,202 |
| EliquisApixaban | 17 | $9,634 |
| DuleraMometasone/Formoterol | 23 | $7,904 |
| Incruse ElliptaUmeclidinium Bromide | 11 | $7,087 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 299 | $6,990 |
| Wixela InhubFluticasone Propion/Salmeterol | 53 | $4,715 |
| Montelukast Sodium | 224 | $3,417 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimOfev, Spiriva Respimat, Stiolto Respimat | $502 | $345,655166 claims |
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta, Incruse Ellipta | $796 | $273,562395 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $229 | $172,898260 claims |
| PfizerEliquis | $15 | $9,63417 claims |
| MerckDulera | $42 | $7,90423 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 57 critical care medicine providers in Oklahoma.
Other critical care medicine in Oklahoma City
- Obaid AshrafOklahoma City$12K
- Michael HarperOklahoma City$6K
- Victoria KyleOklahoma City$4K
- Himanshu BhardwajOklahoma City$3K
- Mark RolfeOklahoma City$3K
- Brent BrownOklahoma City$2K
- Joseph BrewerOklahoma City$2K
- Mircea MihuOklahoma City$2K
- Laura SwantOklahoma City$1K
- Ali AshrafOklahoma City$1K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.